2546-42-1

Basic information

• Product Name: 4-fluorophenyl ethenesulfonate
• Synonyms: 4-fluorophenyl ethenesulfonate
• CAS NO: 2546-42-1
• Molecular Weight: 202.206
• Mol File: 2546-42-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-fluorophenyl ethenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-fluorophenyl ethenesulfonate(2546-42-1)
• EPA Substance Registry System: 4-fluorophenyl ethenesulfonate(2546-42-1)

Safety Data

• Hazardous Substances Data: 2546-42-1(Hazardous Substances Data)

Upstream product

• 371-41-5 4-Fluorophenol 
• 1622-32-8 2-Chloroethanesulfonyl chloride 

Relevant articles and documents

Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide

To develop estrogen receptor (ER) ligands having novel structures and activities, we have explored compounds in which the central hydrophobic core has a more three-dimensional topology than typically found in estrogen ligands and thus exploits the unfilled space in the ligand-binding pocket. Here, we build upon our previous investigations of 7-oxabicyclo[2.2.1]heptene core ligands, by replacing the oxygen bridge with a sulfoxide. These new 7-thiabicyclo[2.2.1] hept-2-ene-7-oxides were conveniently prepared by a Diels-Alder reaction of 3,4-diarylthiophenes with dienophiles in the presence of an oxidant and give cycloadducts with endo stereochemistry. Several new compounds demonstrated high binding affinities with excellent ERα selectivity, but unlike oxabicyclic compounds, which are transcriptional antagonists, most thiabicyclic compounds are potent, ERα-selective agonists. Modeling suggests that the gain in activity of the thiabicyclic compounds arises from their endo stereochemistry that stabilizes an active ER conformation. Further, the disposition of methyl substituents in the phenyl groups attached to the bicyclic core unit contributes to their binding affinity and subtype selectivity.

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer

A strategy to develop chemotherapeutic agents by combining several active groups into a single molecule as a conjugate that can modulate multiple cellular pathways may produce compounds having higher efficacy compared to that of single-target drugs. In th